Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: UCB AE
Woman and Man Max 99 years
UCB AE
Update Il y a 4 ans
Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action
To assess the clinical efficacy of subcutaneous certolizumab pegol 400 mg at week 6, following administration at 0, 2 and 4 weeks for the treatment of signs and symptoms of active Crohn’s Disease (CDA...
Country
None
organs
None
Specialty
None
unknown
More information